.claude/skills/drug-lifecycle-evaluationRuntime, accounts, dependencies, permissions, network behavior and task quality remain untested.
整合单药研发、临床、竞争、交易和专利证据
These states come from the source or distribution context. None of the entries below are SkillVetAI compatibility test results.
These checks parse the fixed package against dated platform rules. They do not execute the Skill or verify task behavior.
.claude/skills/drug-lifecycle-evaluationRuntime, accounts, dependencies, permissions, network behavior and task quality remain untested.
.agents/skills/drug-lifecycle-evaluationRuntime, accounts, dependencies, permissions, network behavior and task quality remain untested.
skills/drug-lifecycle-evaluationRuntime, accounts, dependencies, permissions, network behavior and task quality remain untested.
This command is recorded from the source ecosystem and resolves the registry's latest release. The fixed release shown on this page should be inspected before adoption.
clawhub install @yuanzhian-patsnap/drug-lifecycle-evaluationclawhub inspect @yuanzhian-patsnap/drug-lifecycle-evaluation --version 1.0.0This automated, non-executing scan is bound to this release hash. It is not a safety certification and may contain false positives or false negatives.
This is registry-supplied evidence for the recorded release, not an independent SkillVetAI scan. Check the canonical source for the full report, scanner versions, scope, and current moderation state.
The catalog stores hashes and an inventory summary for change detection. It does not republish the package contents.
sha256:98b3305d2a4c0081c83e6c7be270dfb619f04d0bc642a0ba1e8aec0d92b13ce4agents/openai.yamlreferences/legacy-report-spec.mdskill-card.mdskill.manifest.jsonSKILL.mdInitial release of drug-lifecycle-evaluation. - Integrates single-drug evidence across R&D, clinical, competitive, deal, and patent domains. - Supports lifecycle evaluation for drug asset decision-making, pipeline review, and BD due diligence. - Offers three report depths: screen, standard, and deep, with clear routing for each. - Provides structured workflows for drug normalization, milestone timelines, evidence gathering, comparator logic, and scenario-based strategy assessment. - Emphasizes evidence traceability, data gap disclosure, and quality checkpoints throughout. - Strictly limits output to decision support, not medical, investment, or legal advice.